Carterra LSA for the University of Oxford - Enabling High-Throughput SPR and Antibody Characterisation
牛津大学的 Carterra LSA - 实现高通量 SPR 和抗体表征
基本信息
- 批准号:MR/X012085/1
- 负责人:
- 金额:$ 66.8万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2022
- 资助国家:英国
- 起止时间:2022 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Understanding the interactions that occur between molecules is a central goal in nearly every branch of biomedical research. By understanding how molecules interact, research groups can then use a whole range of approaches to innovate ways of changing these interactions; in many cases this will open up avenues to develop interventions or treatments that can improve human health or prevent disease.Critical to understanding molecular interactions is gaining knowledge about where molecules bind to each other and how quickly they can interact, also known as binding "kinetics". A number of biophysical research instruments are available that enable scientists to accurately measure the binding and kinetics of such molecules. However, a limitation of these machines is their throughput, i.e. only a small number of interactions can be measured at any one time and typically these experiments can take a number of days. Conversely, other fields have greatly advanced their throughput in recent years, building on other exciting advances that enable resarchers to study larger and bigger systems relevant to human health. Consequently, the throughput to measure molecular interactions has become a bottleneck or rate-limiting for many types of research that now wish to study 100s of molecules at once, as opposed to just a few.Recently, a new machine has become available on the market called a "Carterra LSA High-Throughput SPR" platform. The Carterra LSA has rapidly become the clear frontrunner technology worldwide for high-throughput antibody characterisation, used by global pharmaceutical companies and leading US-based academic institutions. The abilities of this machine provide a clear step-change in scientific ambition. For example, the LSA was the primary tool used by Eli Lilly and AbCellera in the discovery of Bamlanivimab, the first COVID-19 therapeutic and fastest biologic ever to reach clinical trials during the pandemic. There is currently, however, no Carterra LSA permanently available in any UK-based academic institution. Access to such a platform is now of strategic importance and critical for the international competitiveness of UK research. This application thus seeks to acquire and enable ease of access to this machine at the University of Oxford. Specific areas of high demand for platform access at the University of Oxford will include:i) vaccine antibody research;ii) development of antibody-based drugs;iii) development of novel antibody-based diagnostics;iv) molecular drug screening for protein-protein interactions; andv) T cell binding and kinetics, relevant to numerous infectious diseases, autoimmune diseases and cancer.All of these areas fall within MRC-relevant research, and will greatly benefit from the unique opportunities of high-throughput screening that will be enabled via access to the LSA.
了解分子之间发生的相互作用几乎是生物医学研究的每个分支的中心目标。通过了解分子如何相互作用,研究小组可以使用一系列的方法来创新改变这些相互作用的方法;在许多情况下,这将为开发能够改善人类健康或预防疾病的干预措施或治疗方法开辟道路。理解分子相互作用的关键是了解分子相互结合的位置以及它们相互作用的速度,也称为结合“动力学”。许多生物物理研究仪器使科学家能够准确地测量这些分子的结合和动力学。然而,这些机器的一个限制是它们的吞吐量,即在任何一次只能测量少量的相互作用,通常这些实验可能需要几天的时间。相反,近年来,在其他令人兴奋的进展的基础上,其他领域的吞吐量大大提高,使研究人员能够研究与人类健康相关的越来越大的系统。因此,测量分子相互作用的通量已经成为许多类型的研究的瓶颈或速度限制,这些研究现在希望一次研究100个分子,而不是几个。最近,市场上出现了一种新的机器,称为“Carterra LSA高通量SPR”平台。Carterra LSA已迅速成为全球高通量抗体表征的前沿技术,被全球制药公司和美国领先的学术机构使用。这台机器的能力为科学抱负提供了一个明显的阶段性变化。例如,LSA是礼来公司和AbCellera公司在发现Bamlanivimab时使用的主要工具,Bamlanivimab是第一个COVID-19治疗药物,也是有史以来最快进入临床试验的生物药物。然而,目前在英国的任何学术机构中都没有永久可用的Carterra LSA。获得这样一个平台现在具有战略重要性,对英国研究的国际竞争力至关重要。因此,本应用程序寻求获得并使牛津大学的这台机器易于访问。牛津大学对平台访问有高需求的具体领域将包括:i)疫苗抗体研究;Ii)抗体类药物的开发;Iii)开发基于抗体的新型诊断方法;Iv)蛋白-蛋白相互作用的分子药物筛选;T细胞结合和动力学,与许多传染病、自身免疫性疾病和癌症有关。所有这些领域都属于mrc相关的研究,并且将极大地受益于高通量筛选的独特机会,这将通过访问LSA而实现。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype
疟疾侵袭蛋白 RH5 的多样化抗原图谱分析鉴定出一种有效的疫苗诱导的人类公共抗体克隆型
- DOI:10.1101/2023.10.04.560576
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Barrett J
- 通讯作者:Barrett J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Simon Draper其他文献
Analysis of peripheral blood B and Tfh cells as predictors of antibody responses in individuals receiving candidate blood-stage malaria vaccines in a Phase Ia clinical trial
- DOI:
10.1186/1475-2875-13-s1-p28 - 发表时间:
2014-09-22 - 期刊:
- 影响因子:3.000
- 作者:
Sean Elias;Kathryn Milne;Cecilia Chui;Susanne Hodgson;Persephone Borrow;Simon Draper - 通讯作者:
Simon Draper
Towards a multi-antigen multi-stage malaria vaccine
- DOI:
10.1186/1475-2875-13-s1-o31 - 发表时间:
2014-09-22 - 期刊:
- 影响因子:3.000
- 作者:
Adrian VS Hill;Sumi Biswas;Simon Draper;Thomas Rampling;Arturo Reyes-Sandoval - 通讯作者:
Arturo Reyes-Sandoval
Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN<sup>®</sup> FILO in healthy UK adults
- DOI:
10.1016/j.jinf.2015.09.031 - 发表时间:
2015-12-01 - 期刊:
- 影响因子:
- 作者:
Tommy Rampling;Katie Ewer;Georgina Bowyer;Danny Wright;Navin Venkatraman;Ruth Payne;Alfredo Nicosia;Nancy Sullivan;Barney Graham;Andrew Pollard;Simon Draper;Ripley Ballou;Alison Lawrie;Sarah Gilbert;Adrian Hill - 通讯作者:
Adrian Hill
Evaluation of simian adenoviral vector AdCh63 expressing MSP-1 as a candidate blood-stage malaria vaccine
- DOI:
10.1016/j.jinf.2009.10.008 - 发表时间:
2009-12-01 - 期刊:
- 影响因子:
- 作者:
Anna Goodman;Sarah Gilbert;Stefano Colloca;Matthew Dicks;Adrian Hill;Simon Draper - 通讯作者:
Simon Draper
Clinical Evaluation Of New Viral Vectored Vaccines Targeting The Plasmodium Falciparum Blood-Stage Antigens; Msp1 And Ama1
- DOI:
10.1016/j.jinf.2011.04.226 - 发表时间:
2011-12-01 - 期刊:
- 影响因子:
- 作者:
Susanne Sheehy;Christopher Duncan;Nicholas Anagnostou;Sean Elias;Fenella Halstead;Katharine Collins;Katie Ewer;Nick Edwards;Alexander Douglas;Katherine Gantlett;Alison Lawrie;Eleanor Berrie;Sarah Moyles;Carole Long;Robert Sinden;Andrew Blagborough;Jittawadee Murphy;Alfredo Nicosia;Adrian Hill;Simon Draper - 通讯作者:
Simon Draper
Simon Draper的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Simon Draper', 18)}}的其他基金
MICA: Large-Scale Vaccine Fill and Phase I Clinical Trial of the RH5.1/Matrix-M Vaccine against Blood-Stage Plasmodium falciparum Malaria
MICA:针对血期恶性疟原虫疟疾的 RH5.1/Matrix-M 疫苗的大规模疫苗填充和 I 期临床试验
- 批准号:
MR/V038427/1 - 财政年份:2021
- 资助金额:
$ 66.8万 - 项目类别:
Research Grant
A. Olotu, Ifakara Health Institute - Immune responses in malaria-exposed children immunised with a new generation blood-stage malaria vaccine.
A. Olotu,伊法卡拉健康研究所 - 接种新一代血期疟疾疫苗的疟疾暴露儿童的免疫反应。
- 批准号:
MR/P020593/1 - 财政年份:2017
- 资助金额:
$ 66.8万 - 项目类别:
Research Grant
MICA: Development and GMP manufacture of a PfRH5 protein vaccine to induce strain-transcending immunity against blood-stage Plasmodium falciparum.
MICA:开发和 GMP 生产 PfRH5 蛋白疫苗,以诱导针对血液阶段恶性疟原虫的菌株超越免疫力。
- 批准号:
MR/K025554/1 - 财政年份:2013
- 资助金额:
$ 66.8万 - 项目类别:
Research Grant
Developmental Clinical Studies - Clinical evaluation of an AdCh63-MVA PvDBP_RII vaccine for blood-stage Plasmodium vivax
发育性临床研究 - AdCh63-MVA PvDBP_RII 血液期疟原虫疫苗的临床评估
- 批准号:
G1100086/1 - 财政年份:2011
- 资助金额:
$ 66.8万 - 项目类别:
Research Grant
Clinical and Immunological Evaluation of T cell- and Antibody-Inducing Viral Vector Vaccines against Blood-Stage Malar
针对血期颧骨的 T 细胞和抗体诱导病毒载体疫苗的临床和免疫学评价
- 批准号:
G1000527/1 - 财政年份:2010
- 资助金额:
$ 66.8万 - 项目类别:
Fellowship
相似国自然基金
基于LSA三维形变模型和深度学习的OPG-CBCT跨模态图像预测方法研究
- 批准号:82301157
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
金黄色葡萄球菌喹奴普丁-达福普汀耐药新基因lsa(E)水平转移机制研究
- 批准号:81301463
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
7Teala MRIを用いたLSA再開通および頭蓋内血管精査法の確立
使用 7Teala MRI 建立 LSA 再通和颅内血管检查
- 批准号:
21K15771 - 财政年份:2021
- 资助金额:
$ 66.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Prediction of vocabulary learning through LSA and the study of its validity: Role of extended input
通过LSA预测词汇学习及其有效性研究:扩展输入的作用
- 批准号:
18K00748 - 财政年份:2018
- 资助金额:
$ 66.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
LSA Satellite Workshop: Foundations of Historical Linguistics
LSA 卫星研讨会:历史语言学基础
- 批准号:
1237202 - 财政年份:2012
- 资助金额:
$ 66.8万 - 项目类别:
Standard Grant
Extending the DSM system with an ASA/LSA spectrum broker
使用 ASA/LSA 频谱代理扩展 DSM 系统
- 批准号:
442463-2012 - 财政年份:2012
- 资助金额:
$ 66.8万 - 项目类别:
Engage Grants Program
Collaborative Research: BPC-LSA: ACM SIGBP: Forming an ACM Special Interest Group to Scale the Impact of BPC Activities
协作研究:BPC-LSA:ACM SIGBP:组建 ACM 特别兴趣小组以扩大 BPC 活动的影响
- 批准号:
1042372 - 财政年份:2010
- 资助金额:
$ 66.8万 - 项目类别:
Standard Grant
BCP-LSA: After-School Apprenticeships
BCP-LSA:课后学徒
- 批准号:
0940604 - 财政年份:2010
- 资助金额:
$ 66.8万 - 项目类别:
Continuing Grant
BPC-LSA: Training High School CS Teachers to Attract More & Diverse Students
BPC-LSA:培训高中计算机科学教师以吸引更多人
- 批准号:
1042452 - 财政年份:2010
- 资助金额:
$ 66.8万 - 项目类别:
Standard Grant
BPC-LSA: Scaling and Adapting Computing Alliance of Hispanic-Serving Institutions (CAHSI) Initiatives
BPC-LSA:西班牙裔服务机构计算联盟 (CAHSI) 计划的扩展和调整
- 批准号:
0940575 - 财政年份:2010
- 资助金额:
$ 66.8万 - 项目类别:
Continuing Grant
BPC-LSA: The Computer Science Collaboration Project
BPC-LSA:计算机科学合作项目
- 批准号:
0940646 - 财政年份:2010
- 资助金额:
$ 66.8万 - 项目类别:
Standard Grant
BPC-LSA: STRONG Computing Pipeline
BPC-LSA:强大的计算管道
- 批准号:
0940592 - 财政年份:2010
- 资助金额:
$ 66.8万 - 项目类别:
Standard Grant